Navigation Links
Targeted drug helps leukemia patients who do not benefit from initial therapy
Date:2/26/2012

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients.

Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and prognosis of patients with CML. Now up to 93 percent of patients who take the drug as initial therapy for CML survive at least eight years, whereas prior to imatinib, patients survived an average of only three to six years.

While imatinib is now the standard drug given after a diagnosis of CML, approximately 15,000 to 20,000 patients in the United States may have started taking imatinib after failing to respond to the previous standard drug for CML, interferon. Like patients who now take imatinib as initial therapy for their cancer, these patients seem to respond well to imatinib, at least in the short term; however, little is known about their long-term prognosis.

To investigate, Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center in Houston, and his colleagues analyzed 368 CML patients from their institution who started taking imatinib after failing to respond to interferon. The team estimated that 68 percent of patients survived for at least 10 years. Previous research indicates that only 20 to 30 percent of patients who do not respond to interferon therapy and have no access to imatinib survive this long.

According to the authors, these findings suggest that most patients can benefit from imatinib after unsuccessful interferon treatments, and they do not have to consider other therapeutic options.


'/>"/>

Contact: Amy Molnar
healthnews@wiley.com
201-748-8844
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related medicine news :

1. Targeted delivery of losartan reduces liver inflammation and scarring
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
4. Targeted agent blocked growth of deadly brain cancer in preclinical studies
5. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
6. New targeted therapy effective in treating advanced prostate cancer
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Women Smokers Targeted on World No Tobacco Day
11. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... (PRWEB) , ... August 20, 2017 , ... State Farm ... of 40 national causes up for a $25,000 grant. If the initiative wins, Gals ... bullying – will expand into the Tri-County area of St. Mary’s, Calvert and Charles ...
(Date:8/19/2017)... ... August 18, 2017 , ... President Donald Trump signed into ... provides for greater public access to over-the-counter (OTC) hearing aids. , The measure ... aids without being seen by a certified and licensed audiologist. , “The ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... diverse community of over 1,000 passionate employees, caregivers, volunteers, thought leaders, researchers, educators ... Stonegate changed ownership, it was time to refresh the carpeting with the goal ...
(Date:8/18/2017)... , ... ... ... For Immediate Release                Contact: ... Shows Young Women Seek Sex and Relationship Advice from their ...
(Date:8/18/2017)... Ca (PRWEB) , ... August 18, 2017 , ... ... quality liquid handling handheld devices. Through an educational webinar, they will present the ... users a chance to learn how easy you can automate everyday pipetting tasks. ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
(Date:7/26/2017)... -- E.I. Medical Imaging (EIMI) has partnered with Dr. ... the worlds first ultrasound system to be used underwater to ... In preparation for a piece produced by Icon films ... Guttridge approached EIMI with the idea of an underwater ultrasound ... underwater. EIMI produces ...
(Date:7/26/2017)... RIVIERA BEACH, Fla. , July 26, 2017 /PRNewswire/ ... completion of enrollment of our clinical trial evaluating Altemia ... Sickle Cell Anemia (SCA) and Sickle Cell Disease (SCD). ... study to evaluate the efficacy and safety of Altemia ... This trial is conducted under US IND 125274. ...
Breaking Medicine Technology: